Secukinumab, the first interleukin-17A inhibitor, is effective in psoriatic arthritis
Two pivotal phase III studies ( FUTURE 1 and FUTURE 2 ) of Secukinumab ( AIN457 ) in psoriatic arthritis ( PsA ) met primary and key secondary endpoints.
Endpoints included improving signs and sympt ...
read article